黑色素瘤前哨淋巴结阳性风险预测模型:系统综述与Meta分析
该研究系统检索Embase和MEDLINE至2024年5月1日,纳入开发或验证黑色素瘤前哨淋巴结活检(SLNB)阳性风险预测模型的研究,采用随机效应Meta分析合并C统计量。共纳入23篇文章描述21个模型开发、20个外部验证涉及8个模型,所有模型合并加权C统计量为0.78(95%CI 0.74-0.81),异质性显著(I2=97.4%)。
要点
- 所有SLNB阳性风险预测模型的合并加权C统计量为0.78(95%CI 0.74-0.81)。
- MSKCC模型外部验证合并C统计量0.73(95%CI 0.69-0.78),MIA模型为0.70(95%CI 0.66-0.74)。
核心结论
- 多种SLNB阳性风险预测模型已经过外部验证,并显示出较强的判别性能。
研究设计与样本
- 系统综述与Meta分析,检索Embase和MEDLINE从建库至2024年5月1日的英文文献。
- 纳入开发或验证黑色素瘤SLNB阳性风险预测模型并报告模型判别指标的研究,由2名评价者筛选,分歧由第3人裁定。
- 共纳入23篇文章,描述21个模型开发、20个外部验证涉及8个模型,以及9个可提供个体化风险估计的模型。
主要发现
- 所有风险预测模型的合并加权C统计量为0.78(95%CI 0.74-0.81),异质性显著(I2=97.4%),Meta回归未能解释异质性。
- MSKCC和MIA模型最常进行外部验证,判别性能较强且相当:MSKCC合并加权C统计量0.73(95%CI 0.69-0.78),MIA为0.70(95%CI 0.66-0.74)。
局限性
- 合并C统计量存在显著异质性(I2=97.4%),且Meta回归未能解释异质性来源。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is a need to identify the best performing risk prediction model for sentinel lymph node biopsy (SLNB) positivity in melanoma. OBJECTIVE: To comprehensively review the characteristics and discriminative performance of existing risk prediction models for SLNB positivity in melanoma. DATA SOURCES: Embase and MEDLINE were searched from inception to May 1, 2024, for English language articles. STUDY SELECTION: All studies that either developed or validated a risk prediction model (defined as any calculator that combined more than 1 variable to provide a patient estimate for probability of melanoma SLNB positivity) with a corresponding measure of model discrimination were considered for inclusion by 2 reviewers, with disagreements adjudicated by a third reviewer. DATA EXTRACTION AND SYNTHESIS: Data were extracted in duplicate according to Data Extraction for Systematic Reviews of Prediction Modeling Studies, Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis, and Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines. Effects were pooled using random-effects meta-analysis. MAIN OUTCOME AND MEASURES: The primary outcome was the mean pooled C statistic. Heterogeneity was assessed using the I2 statistic. RESULTS: In total, 23 articles describing the development of 21 different risk prediction models for SLNB positivity, 20 external validations of 8 different risk prediction models, and 9 models that included sufficient information to obtain individualized patient risk estimates in routine preprocedural clinical practice were identified. Among all risk prediction models, the pooled weighted C statistic was 0.78 (95% CI, 0.74-0.81) with significant heterogeneity (I2 = 97.4%) that was not explained in meta-regression. The Memorial Sloan Kettering Cancer Center and Melanoma Institute of Australia models were most frequently externally validated with both having strong and comparable discriminative performance (pooled weighted C statistic, 0.73; 95% CI, 0.69-0.78 vs pooled weighted C statistic, 0.70; 95% CI, 0.66-0.74). Discrimination was not significantly different between models that included gene expression profiles (pooled C statistic, 0.83; 95% CI, 0.76-0.90) and those that only used clinicopathologic features (pooled C statistic, 0.77; 95% CI, 0.73-0.81) (P = .11). CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis found several risk prediction models that have been externally validated with strong discriminative performance. Further research is needed to evaluate the associations of their implementation with preprocedural care.
引用
- Ma B, Gandhi M, Czyz S, et al. Risk Prediction Models for Sentinel Node Positivity in Melanoma: A Systematic Review and Meta-Analysis. JAMA Dermatol. 2025. PMID: 40072444. doi:10.1001/jamadermatol.2025.0113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。